Rybelsus®

Semaglutide

Rybelsus® tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus® can be prescribed when other diabetes medicines have been tried without success and should be used together with diet and exercise. Rybelsus® tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating.
more
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 71.89
lei 6470.04lei 71.89
lei 862.22
60 tablet
Free AirMail shipping Hot
lei 76.68
lei 4600.85lei 76.68
lei 287.33
30 tablet
Free AirMail shipping Hot
lei 81.47
lei 2444.09lei 81.47
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 86.27
lei 7764.10lei 86.27
lei 430.87
60 tablet
Free AirMail shipping Hot
lei 88.66
lei 5319.77lei 88.66
lei 143.54
30 tablet
Free AirMail shipping Hot
lei 91.06
lei 2731.66lei 91.06
Package Per pill Price Savings Order
90 tablet
Free AirMail shipping Hot
lei 103.04
lei 9273.83lei 103.04
lei 430.87
60 tablet
Free AirMail shipping Hot
lei 105.44
lei 6326.26lei 105.44
lei 143.54
30 tablet
Free AirMail shipping Hot
lei 107.83
lei 3234.90lei 107.83
Rybelsus

Brand(s)

Manufacturer

  • Novo Nordisc India Pvt. Ltd

Disease(s)

  • Type 2 Diabetes Mellitus / High Blood Sugar

Rybelsus® tablets

What is Rybelsus?

Rybelsus tablets (semaglutide) is a prescription medicine used in adults with type 2 diabetes mellitus to decrease blood sugar levels. Rybelsus can be prescribed when other diabetes medicines have been tried without success, and should be used together with diet and exercise.

Rybelsus tablets work to lower blood sugar (glucose) levels by increasing how much insulin is released and decreasing glucagon secretion. This medicine also may slow gastric emptying after eating. Rybelsus is from the class of medicines called GLP-1 receptor agonists.
Rybelsus is not for treating type 1 diabetes.
Rybelsus was first approved by the FDA on September 20, 2019.

Warnings

You should not use Rybelsus if you have multiple endocrine neoplasia type 2 (tumors in your glands), a personal or family history of medullary thyroid cancer, insulin-dependent diabetes, or diabetic ketoacidosis.
Call your doctor at once if you have signs of a thyroid tumor, such as swelling or a lump in your neck, trouble swallowing, a hoarse voice, or shortness of breath.